Janssen partners with NHS for dementia innovation challenge

pharmafield logo - pharma news

Marco Mohwinkel Janssen web Janssen Healthcare Innovation has partnered with the NHS to launch stage two of the first NHS Innovation Challenge Prize for Dementia.

The partnership is offering up to £150,000 for innovative solutions from multi-disciplinary dementia care teams that deliver an integrated health, care and support service.

This is the first time an industry partner has supported the NHS in its Challenge Prize programme, which has been running for three years.

While the NHS currently spends £23 billion per year on dementia care, there is a high level of unmet need. Poor integration of care is a major problem, as dementia care spans primary, secondary and social care.

The challenge definition states: “The challenge is to deliver better outcomes for people with dementia and their carers through services that are integrated and designed around the person with dementia and not the system.”

Applications should be submitted by two or more organisations providing healthcare, social care or support to people with dementia. Entrants will need to show how they are working together and achieving outcomes such as better access to care and treatment, reduced hospital and care home admissions, and cost savings.

Marco Mohwinckel of Janssen Healthcare Innovation said: “We need to see a shift in the way dementia care is organised and delivered in the UK if we are to deliver better outcomes for patients and their carers. It’s crucial that care is co-ordinated, patient-centred and tailored to the individual needs of the patient and their family.

“Janssen Healthcare Innovation is delighted to be partnering with the NHS on this important challenge prize to help drive real change for those affected by dementia.”

The deadline for submissions for the challenge is Wednesday 4 September 2013. For more information, see www.nhschallengeprizes.org

Janssen Healthcare Innovation is the entrepreneurial team within Janssen R&D, part of the Janssen pharmaceutical group within Johnson & Johnson.